MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Olfactive Biosolutions, a leader in ectopic and chemosensory receptor technology, recently filed a U.S. patent for Protenx, a proprietary line of breakthrough food ingredient formulations. The Protenx weight loss formula for example activates the same dual GLP-1 and GIP pathways as tirzepatide, to facilitate weight loss and blood sugar regulation.

加利福尼亚州山景城（商业新闻短讯）--异位和化学感受受体技术的领导者Olfactive Biosolutions最近为Protenx申请了美国专利，Protenx是突破性食品成分配方的专有产品线。例如，Protenx减肥配方激活了与替罗西肽相同的双重GLP-1和GIP途径，以促进体重减轻和血糖调节。

Protenx weight loss formula integrates into consumer products, bringing to them the potential of achieving benefits consistent with current weight loss prescription-only pharmaceuticals..

Protenx减肥配方集成到消费品中，为他们带来了与当前减肥处方药一致的益处的潜力。。

Protenx accomplishes this while avoiding harmful side effects and high cost. Blended into everyday food and drinks such as coffee, Protenx does not require any changes in consumer routines. With its proprietary blend of food ingredients, Protenx targets olfactory and taste receptors in the gut (ectopic receptors) and elsewhere throughout the body to induce similar effects as pharmaceutical agents, to:.

Protenx可以做到这一点，同时避免了有害的副作用和高昂的成本。将Protenx融入日常食品和饮料（如咖啡）中，不需要改变消费者的日常习惯。凭借其专有的食物成分混合物，Protenx靶向肠道和全身其他部位的嗅觉和味觉受体（异位受体），以诱导与药物类似的作用，从而达到：。

Induce weight loss

诱导体重减轻

Lower blood sugar

降低血糖

Slow gastric emptying

胃排空缓慢

Lower blood pressure

降低血压

Increase bronchodilation

增加支气管扩张

Promote muscle gain

促进肌肉增加

Increase bone remodeling

增加骨骼重塑

Reduce inflammation, and

减少炎症，以及

Induce the release of neurotransmitters such as serotonin, GABA and dopamine.

诱导神经递质的释放，如血清素、GABA和多巴胺。

Olfactive Biosolutions can then use its knowledge of olfactory and taste receptors to adjust the hedonics, to ensure the products maintain the same flavor and aroma.

然后，嗅觉生物溶液可以利用其嗅觉和味觉受体的知识来调整享乐，以确保产品保持相同的风味和香气。

Protenx is slated for general availability in Q4 2024. Protenx proprietary formulations may be added to new or existing consumer products. The Protenx patent also allows for administration including but not limited to topically, sublingual lozenges, inhaled or administered in multiple other ways.

Protenx计划于2024年第四季度正式上市。Protenx专有配方可添加到新的或现有的消费品中。Protenx专利还允许给药，包括但不限于局部，舌下含片，吸入或以多种其他方式给药。

“We are excited to have filed patents for Protenx. With related products currently in development, we will offer consumers a comprehensive platform that can safely control their weight, blood sugar, blood pressure and other conditions,” said Nils Lommerin, President and CEO of Olfactive Biosolutions..

Olfactive Biosolutions总裁兼首席执行官尼尔斯·洛梅林（NilsLommerin）表示：“我们很高兴能为Protenx申请专利。随着相关产品的开发，我们将为消费者提供一个全面的平台，可以安全地控制他们的体重、血糖、血压和其他状况。”。。

Using the ectopic, olfactory and taste receptor genes along with selected genes for intracellular signaling, Olfactive Biosolutions has engineered mammalian biosensor cells to behave in a manner like the ectopic, olfactory and taste neuron cells in humans. Olfactive Biosolutions biosensor cells produce discreet, measurable luminescent signals when an engineered receptor on the cell’s surface binds to its complementary ingredient molecules..

使用异位，嗅觉和味觉受体基因以及用于细胞内信号传导的选定基因，Olfactive Biosolutions已经设计了哺乳动物生物传感器细胞，其行为方式类似于人类的异位，嗅觉和味觉神经元细胞。当细胞表面的工程受体与其互补成分分子结合时，嗅觉生物溶液生物传感器细胞会产生谨慎，可测量的发光信号。。

Using multiple receptors in a multi-well disposable plate, an ingredient sample can be presented to numerous human ectopic, olfactory and taste receptors to determine which receptors are activated. Biochemical parameters such as EC50s (the amount of a chemical required to activate a receptor to 50 percent of its maximum activity) and the limit of detection (LOD) of the molecules present in the samples can be determined.

在多孔一次性平板中使用多个受体，可以将成分样品呈现给许多人类异位，嗅觉和味觉受体，以确定哪些受体被激活。可以确定生化参数，例如EC50（将受体激活至其最大活性的50%所需的化学物质的量）和样品中存在的分子的检测限（LOD）。

This information allows a sample to be chemically characterized with great specificity and sensitivity..

这些信息可以使样品具有很高的特异性和敏感性。。

“Protenx is the culmination of years of work and the efforts of many Olfactive Biosolutions dedicated scientists,” said Dr. William Harries, the company’s chief scientist.

该公司首席科学家威廉·哈里斯（WilliamHarries）博士说：“Protenx是多年工作和许多专注于嗅觉生物解决方案的科学家努力的结晶。”。

About Olfactive Biosolutions

关于嗅觉生物溶液

Olfactive Biosolutions has developed world-leading receptor technology and expertise in both ectopic receptors in the gut, lungs, skin, heart, blood and elsewhere, and olfactory and taste receptors in the nose and tongue.

Olfactive Biosolutions在肠道、肺部、皮肤、心脏、血液和其他地方的异位受体以及鼻子和舌头的嗅觉和味觉受体方面开发了世界领先的受体技术和专业知识。

Its unique technology demonstrates how ectopic receptors often perform the same physiologic tasks as active pharmaceutical ingredients or APIs, and what ligands activate or inhibit them.

它独特的技术证明了异位受体如何经常执行与活性药物成分或API相同的生理任务，以及哪些配体激活或抑制它们。

The same technology accurately measures the actual taste and smell of existing products, allowing the company to anchor the hedonics of a customer’s product, so it tastes and smells exactly like the original even after the addition of Protenx.

同样的技术可以准确地测量现有产品的实际味道和气味，使公司能够定位客户产品的享乐，因此即使添加了Protenx，它的味道和气味也与原始产品一模一样。

The Olfactive Biosolutions team has deep expertise in receptor protein science, artificial intelligence (AI) and the food & beverage industry. The company has several well-known biotechnology and AI advisors from academia and the corporate world.

Olfactive Biosolutions团队在受体蛋白科学、人工智能（AI）和食品饮料行业拥有丰富的专业知识。该公司拥有多名来自学术界和企业界的知名生物技术和人工智能顾问。

To learn more, visit https://olfactive.bio or follow us on LinkedIn.

要了解更多信息，请访问https://olfactive.bio或者在LinkedIn上关注我们。